
Sign up to save your podcasts
Or


In 2025, the U.S. FDA removed the “black box” warnings from menopausal hormone therapy products – but what does that actually mean for patients? For decades, many women have navigated perimenopause and menopause with limited information, few effective options, and little validation of their symptoms. In part one of this two-part series, we speak with Sharon Malone, MD, board-certified OB-GYN and chief medical advisor for Alloy Women’s Health, about what happens during the menopausal transition, why symptoms can feel chaotic and unpredictable, and how misinterpretations of past research have shaped – and often restricted – women’s care.
Credits
See omnystudio.com/listener for privacy information.
By WebMD4.5
113113 ratings
In 2025, the U.S. FDA removed the “black box” warnings from menopausal hormone therapy products – but what does that actually mean for patients? For decades, many women have navigated perimenopause and menopause with limited information, few effective options, and little validation of their symptoms. In part one of this two-part series, we speak with Sharon Malone, MD, board-certified OB-GYN and chief medical advisor for Alloy Women’s Health, about what happens during the menopausal transition, why symptoms can feel chaotic and unpredictable, and how misinterpretations of past research have shaped – and often restricted – women’s care.
Credits
See omnystudio.com/listener for privacy information.

21,954 Listeners

43,687 Listeners

1,652 Listeners

1,406 Listeners

4,253 Listeners

113,121 Listeners

56,944 Listeners

6,457 Listeners

3,470 Listeners

9,194 Listeners

8,043 Listeners

6,446 Listeners

8,238 Listeners

6,462 Listeners

633 Listeners